Vicky Hsu

1.2k total citations
12 papers, 960 citations indexed

About

Vicky Hsu is a scholar working on Pharmacology, Pediatrics, Perinatology and Child Health and Oncology. According to data from OpenAlex, Vicky Hsu has authored 12 papers receiving a total of 960 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pharmacology, 5 papers in Pediatrics, Perinatology and Child Health and 4 papers in Oncology. Recurrent topics in Vicky Hsu's work include Pharmacogenetics and Drug Metabolism (6 papers), Drug Transport and Resistance Mechanisms (4 papers) and Pharmacological Effects and Toxicity Studies (4 papers). Vicky Hsu is often cited by papers focused on Pharmacogenetics and Drug Metabolism (6 papers), Drug Transport and Resistance Mechanisms (4 papers) and Pharmacological Effects and Toxicity Studies (4 papers). Vicky Hsu collaborates with scholars based in United States, Sweden and Canada. Vicky Hsu's co-authors include Ping Zhao, Vikram Sinha, Christian Wagner, Joseph A. Grillo, Yuzhuo Pan, S-M Huang, Y. Pan, Kellie S. Reynolds, Lei Zhang and Rosane Charlab and has published in prestigious journals such as Clinical Cancer Research, Clinical Pharmacology & Therapeutics and Clinical Pharmacokinetics.

In The Last Decade

Vicky Hsu

12 papers receiving 949 citations

Peers

Countries citing papers authored by Vicky Hsu

Since Specialization

Citations

This map shows the geographic impact of Vicky Hsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vicky Hsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vicky Hsu more than expected).

Fields of papers citing papers by Vicky Hsu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vicky Hsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vicky Hsu. The network helps show where Vicky Hsu may publish in the future.

Co-authorship network of co-authors of Vicky Hsu

This figure shows the co-authorship network connecting the top 25 collaborators of Vicky Hsu. A scholar is included among the top collaborators of Vicky Hsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vicky Hsu. Vicky Hsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation 2024 ·Clinical Cancer Research ·(unknown), Edwin C.Y. Chow, Alexei Ionan, (unknown), Shwu‐Luan Lee, Vicky Hsu, Manuela Grimstein, (unknown), Jielin Sun, Rosane Charlab, Brenda J. Gehrke, Jonathon Vallejo, Lori A. Ehrlich, R. Angelo de Claro, Marc R. Theoret	2
2	FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma 2020 ·Clinical Cancer Research ·Elaine Chang, Chana Weinstock, Lijun Zhang, Rosane Charlab, Sarah E. Dorff, Yutao Gong, Vicky Hsu, Fang Li, Tiffany K. Ricks, Pengfei Song, Shenghui Tang, Peter Waldron, Jingyu Yu, Eias Zahalka, Kirsten B. Goldberg, Richard Pazdur, Marc R. Theoret, Amna Ibrahim, Julia A. Beaver	135
3	FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation 2019 ·Clinical Cancer Research ·Kelly J. Norsworthy, Lola Luo, Vicky Hsu, Ramadevi Gudi, Sarah E. Dorff, Donna Przepiorka, Albert Deisseroth, Yuan Li Shen, Christopher M. Sheth, Rosane Charlab, Gene M. Williams, Kirsten B. Goldberg, Ann T. Farrell, Richard Pazdur	102
4	Predictive Performance of Physiologically-Based Pharmacokinetic Models in Predicting Drug–Drug Interactions Involving Enzyme Modulation 2018 ·Clinical Pharmacokinetics ·Chia‐Hsiang Hsueh, Vicky Hsu, Yuzhuo Pan, Ping Zhao	16
5	Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches 2018 ·Clinical Pharmacology & Therapeutics ·Yingying Guo, Xiaoyan Chu, Neil Parrott, Kim L. R. Brouwer, Vicky Hsu, Swati Nagar, Pär Matsson, Pradeep Sharma, Jan Snoeys, Yuichi Sugiyama, Daniel Tatosian, Jashvant D. Unadkat, Shiew‐Mei Huang, Aleksandra Galetin	88
6	PBPK Modeling of the Effect of Reduced Kidney Function on the Pharmacokinetics of Drugs Excreted Renally by Organic Anion Transporters 2017 ·Clinical Pharmacology & Therapeutics ·(unknown), Vicky Hsu, Ping Zhao, L Zhang, KM Giacomini, Huang Sm	66
7	The Application of Physiologically Based Pharmacokinetic Modeling to Predict the Role of Drug Transporters: Scientific and Regulatory Perspectives 2016 ·The Journal of Clinical Pharmacology ·Yuzhuo Pan, Vicky Hsu, Manuela Grimstein, Lei Zhang, Vikram Arya, Vikram Sinha, Joseph A. Grillo, Ping Zhao	39
8	Predicting the Effect of CYP3A Inducers on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA 2015 ·Clinical Pharmacokinetics ·Christian Wagner, Yuzhuo Pan, Vicky Hsu, Vikram Sinha, Ping Zhao	78
9	Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK 2015 ·CPT Pharmacometrics & Systems Pharmacology ·Christian Wagner, Ping Zhao, Y. Pan, Vicky Hsu, Joseph A. Grillo, S-M Huang, Vikram Sinha	217
10	Predicting the Effect of Cytochrome P450 Inhibitors on Substrate Drugs: Analysis of Physiologically Based Pharmacokinetic Modeling Submissions to the US Food and Drug Administration 2014 ·Clinical Pharmacokinetics ·Christian Wagner, Yuzhuo Pan, Vicky Hsu, Joseph A. Grillo, Lei Zhang, Kellie S. Reynolds, Vikram Sinha, Ping Zhao	119
11	Towards Quantitation of the Effects of Renal Impairment and Probenecid Inhibition on Kidney Uptake and Efflux Transporters, Using Physiologically Based Pharmacokinetic Modelling and Simulations 2013 ·Clinical Pharmacokinetics ·Vicky Hsu, Manuela de Lima Toccafondo Vieira, Ping Zhao, Lei Zhang, Jenny Zheng, Anna Nordmark, Eva Gil Berglund, Kathleen M. Giacomini, Shiew‐Mei Huang	77
12	The Prevalence of Major Depressive Disorder and Low Self-Esteem in Medical Inpatients 1996 ·The Canadian Journal of Psychiatry ·Peter H. Silverstone, (unknown), (unknown), Vicky Hsu, (unknown)	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact